2013 IDSA clinical practice guideline for vaccination of the immunocompromised host

Clinical Infectious Diseases

Volumn 58, Issue 3, 2014, Pages

  Rubin, Lorry G ^a   Levin, Myron J ^b   Ljungman, Per ^c,d   Davies, E Graham ^e   Avery, Robin ^f   Tomblyn, Marcie ^g   Bousvaros, Athos ^h   Dhanireddy, Shireesha ⁱ   Sung, Lillian ^j   Keyserling, Harry ^k   Kang, Insoo ^l  

^a Children's Medical Center   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e Great Ormond Street Hospital and Institute of Child Health ^*  (United Kingdom)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^h BOSTON CHILDREN S HOSPITAL   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j HOSPITAL FOR SICK CHILDREN   (Canada)

^k EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

asplenic patients; immunization; immunocompromised patients; immunodeficiency patients; immunosuppression; vaccination

Indexed keywords

INFLUENZA VACCINE; VACCINE; VARICELLA ZOSTER VACCINE; BCG VACCINE; CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B MENINGOCOCCUS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INACTIVATED VACCINE; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE; TYPHOID VACCINE; WART VIRUS VACCINE; YELLOW FEVER VACCINE;

ARTICLE; ASPLENIA; CHICKENPOX; CHRONIC INFLAMMATION; CONSENSUS DEVELOPMENT; FAMILY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; NEOPLASM; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPONSIBILITY; SICKLE CELL ANEMIA; TRAVEL; VACCINATION; ADOLESCENT; ADULT; AGED; ASPLENIC PATIENTS; CHILD; IMMUNIZATION; IMMUNOCOMPROMISED PATIENTS; IMMUNODEFICIENCY PATIENTS; INFANT; METHODOLOGY; MIDDLE AGED; PRESCHOOL CHILD; YOUNG ADULT; CANCER PATIENT; CHRONIC DISEASE; GRAFT RECIPIENT; HOUSEHOLD; HUMORAL IMMUNE DEFICIENCY; IMMUNE DEFICIENCY; IMMUNOTHERAPY; INFECTION RISK; INFLAMMATORY DISEASE; INNATE IMMUNITY; PRIMARY MEDICAL CARE;

ASPLENIC PATIENTS; IMMUNIZATION; IMMUNOCOMPROMISED PATIENTS; IMMUNODEFICIENCY PATIENTS; IMMUNOSUPPRESSION; VACCINATION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNOCOMPROMISED HOST; INFANT; MIDDLE AGED; VACCINATION; YOUNG ADULT;

EID: 84892707488     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit684     Document Type: Article

References (484)

1. Burroughs M, Moscona A. Immunization of pediatric solid organ transplant candidates and recipients. Clin Infect Dis 2000; 30:857-69.
2. Davies K, Woo P. Immunization in rheumatic diseases of childhood: an audit of the clinical practice of British Paediatric Rheumatology Group members and a review of the evidence. Rheumatology (Oxford) 2002; 41:937-41.
3. Bridges MJ, Coady D, Kelly CA, Hamilton J, Heycock C. Factors influencing uptake of influenza vaccination in patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62:685.
4. Melmed GY, Ippoliti AF, Papadakis KA, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol 2006; 101:1834-40.
5. Stratton K, Andrew F, Rusch E, Clayton E. Adverse effects of vaccines: evidence and causality. Washington, DC: The National Academies Press, 2012.
6. Field MJ, Lohr KN. Institute of Medicine committee to advise the Public Health Service on clinical practice guidelines (1990). Clinical practice guidelines: directions for a new program. Washington, DC: National Academy Press, 1990:52-77.
7. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. http://aidsinfo.nih. gov/guidelines/html/5/pediatric-oi-prevention-and-treatment-guidelines/0. Accessed 8 November 2013.
8. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:229-35.
9. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336:924-6.
10. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57:1-30.; quiz CE2-4.
11. No authors listed. General recommendations on immunization recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1-64.
12. Halasa NB, Shankar SM, Talbot TR, et al. Incidence of invasive pneu-mococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 2007; 44:1428-33.
13. Atashili J, Kalilani L, Adimora AA. Efficacy and clinical effectiveness of influenza vaccines in HIV-infected individuals: a meta-analysis. BMC Infect Dis 2006; 6:138.
14. Heijstek MW, Ott de Bruin LM, Bijl M, et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis 2011; 70:1704-12.
15. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15:1143-238.
16. Kano H, Mizuta K, Sakakihara Y, et al. Efficacy and safety of immunization for pre-and post-liver transplant children. Transplantation 2002; 74:543-50.
17. Zamora I, Simon JM, Da Silva ME, Piqueras AI. Attenuated varicella virus vaccine in children with renal transplants. Pediatr Nephrol 1994; 8:190-2.
18. Weinberg A, Horslen SP, Kaufman SS, et al. Safety and immunogenic-ity of varicella-zoster virus vaccine in pediatric liver and intestine transplant recipients. Am J Transplant 2006; 6:565-8.
19. Gershon AA, Steinberg SP, Gelb L, et al. Live attenuated varicella vaccine. Efficacy for children with leukemia in remission. JAMA 1984; 252:355-62.
20. Son M, Shapiro ED, LaRussa P, et al. Effectiveness of varicella vaccine in children infected with HIV. J Infect Dis 2010; 201:1806-10.
21. Olin P, Hallander HO, Gustafsson L, Reizenstein E, Storsaeter J. How to make sense of pertussis immunogenicity data. Clin Infect Dis 2001; 33 (Suppl 4):S288-91.
22. Cherry JD, Gornbein J, Heininger U, Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998; 16:1901-6.
23. Rubin LG. Anticapsular antibody requirements for protection against experimental Haemophilus influenzae type b bacteremia after splenec-tomy. Infect Immun 1988; 56:984-6.
24. Hosea SW, Brown EJ, Hamburger MI, Frank MM. Opsonic requirements for intravascular clearance after splenectomy. N Engl J Med 1981; 304:245-50.
25. Ohmit SE, Petrie JG, Cross RT, Johnson E, Monto AS. Influenza hem-agglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J Infect Dis 2011; 204:1879-85.
26. Henckaerts I, Durant N, De Grave D, Schuerman L, Poolman J. Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children. Vaccine 2007; 25:2518-27.
27. Usinger WR, Lucas AH. Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides. Infect Immun 1999; 67:2366-70.
28. Arvin AM. Immune responses to varicella-zoster virus. Infect Dis Clin North Am 1996; 10:529-70.
29. No authors listed. Influenza vaccination coverage among pregnant women-United States, 2010-11 influenza season. MMWR Morb Mortal Wkly Rep 2011; 60:1078-82.
30. Potter J, Stott DJ, Roberts MA, et al. Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients. J Infect Dis 1997; 175:1-6.
31. Carman WF, Elder AG, Wallace LA, et al. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial. Lancet 2000; 355:93-7.
32. No authors listed. Influenza vaccination coverage among health-care personnel-United States, 2010-11 influenza season. MMWR Morb Mortal Wkly Rep 2011; 60:1073-7.
33. Castagnini LA, Healy CM, Rench MA, Wootton SH, Munoz FM, Baker CJ. Impact of maternal postpartum tetanus and diphtheria toxoids and acellular pertussis immunization on infant pertussis infection. Clin Infect Dis 2012; 54:78-84.
34. No authors listed. Recommended immunization schedules for persons aged 0 through 18 Years-United States, 2012. MMWR Morb Mortal Wkly Rep 2012; 61:1-4.
35. Block SL, Yogev R, Hayden FG, Ambrose CS, Zeng W, Walker RE. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age. Vaccine 2008; 26:4940-6.
36. Talbot TR, Crocker DD, Peters J, et al. Duration of virus shedding after trivalent intranasal live attenuated influenza vaccination in adults. Infect Control Hosp Epidemiol 2005; 26:494-500.
37. Ali T, Scott N, Kallas W, et al. Detection of influenza antigen with rapid antibody-based tests after intranasal influenza vaccination (FluMist). Clin Infect Dis 2004; 38:760-2.
38. King JC Jr., Treanor J, Fast PE, et al. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, triva-lent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect Dis 2000; 181:725-8.
39. King JC Jr., Fast PE, Zangwill KM, et al. Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children. Pediatr Infect Dis J 2001; 20:1124-31.
40. Vesikari T, Karvonen A, Korhonen T, et al. A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. Pediatr Infect Dis J 2006; 25:590-5.
41. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010; 59:1-62.
42. Losonsky GA, Fishaut JM, Strussenberg J, Ogra PL. Effect of immunization against rubella on lactation products. II. Maternal-neonatal interactions. J Infect Dis 1982; 145:661-6.
43. Traiber C, Coelho-Amaral P, Ritter VR, Winge A. Infant meningoen-cephalitis caused by yellow fever vaccine virus transmitted via breast-milk. J Pediatr (Rio J) 2011; 87:269-72.
44. Diaz PS, Au D, Smith S, Amylon M, Link M, Arvin AM. Lack of transmission of the live attenuated varicella vaccine virus to immunocom-promised children after immunization of their siblings. Pediatrics 1991; 87:166-70.
45. Marin M, Guris D, Chaves SS, Schmid S, Seward JF. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56:1-40.
46. Sharrar RG, LaRussa P, Galea SA, et al. The postmarketing safety profile of varicella vaccine. Vaccine 2000; 19:916-23.
47. Grossberg R, Harpaz R, Rubtcova E, Loparev V, Seward JF, Schmid DS. Secondary transmission of varicella vaccine virus in a chronic care facility for children. J Pediatr 2006; 148:842-4.
48. Anderson EJ. Rotavirus vaccines: viral shedding and risk of transmission. Lancet Infect Dis 2008; 8:642-9.
49. Payne D, Edwards K, Bowen M. Sibling transmission of vaccine-derived rotavirus (RotaTeq) associated with rotavirus gastroenteritis (case report). Pediatrics 2010; 125:e438-e41.
50. Rivera L, Pena LM, Stainier I, et al. Horizontal transmission of a human rotavirus vaccine strain-a randomized, placebo-controlled study in twins. Vaccine 2011; 29:9508-13.
51. Bernstein HH, Starke JR. Policy statement-recommendation for mandatory influenza immunization of all health care personnel. Pediatrics 2010; 126:809-15.
52. Babcock HM, Gemeinhart N, Jones M, Dunagan WC, Woeltje KF. Mandatory influenza vaccination of health care workers: translating policy to practice. Clin Infect Dis 2010; 50:459-64.
53. Pearson ML, Bridges CB, Harper SA. Influenza vaccination of healthcare personnel: recommendations of the Healthcare Infection Control Practices Advisory Committee (HICPAC) and the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55:1-16.
54. No authors listed. Paralytic poliomyelitis-United States 1980-1994. MMWR Morb Mortal Wkly Rep 1997; 46: 79-83.
55. DeVries AS, Harper J, Murray A, et al. Vaccine-derived poliomyelitis 12 years after infection in Minnesota. N Engl J Med 2011; 364:2316-23.
56. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006; 55:1-33; quiz CE1-4.
57. Fonseca MO, Pang LW, de Paula Cavalheiro N, Barone AA, Heloisa Lopes M. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 2005; 23:2902-8.
58. Launay O, van der Vliet D, Rosenberg AR, et al. Safety and immuno-genicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. JAMA 2011; 305:1432-40.
59. Atkinson WL, Kroger A, Pickering LK. Section 1: General aspects of vaccination, Part 7: General immunization practices. Vaccine 2008; 57:723.
60. Jong E, Freedman D. The immunocompromised traveler. 2010, New York, NY: Oxford University Press.
61. Brunette G, Kozarsky P, Magil l A, Shlim D. CDC health information for international travel 2010. Yellow Book, 2010, New York, NY: Oxford University Press.
62. Staples JE, Gershman M, Fischer M. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59:1-27.
63. Mota LM, Oliveira AC, Lima RA, Santos-Neto LL, Tauil PL. Vaccination against yellow fever among patients on immunosuppressors with diagnoses of rheumatic diseases. Rev Soc Bras Med Trop 2009; 42:23-7.
64. Rio B. Vaccination for yellow fever after bone marrow transplantation. Bone Marrow Transplant, 1996; 17(1 Suppl):95.
65. Gowda R, Cartwright K, Bremner JA, Green ST. Yellow fever vaccine: a successful vaccination of an immunocompromised patient. Eur J Haematol 2004; 72:299-301.
66. Yax JA, Farnon EC, Cary Engleberg N. Successful immunization of an allogeneic bone marrow transplant recipient with live, attenuated yellow fever vaccine. J Travel Med 2009; 16:365-7.
67. Veit O, Niedrig M, Chapuis-Taillard C, et al. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis 2009; 48:659-66.
68. Sidibe M, Yactayo S, Kalle A, et al. Immunogenicity and safety of yellow fever vaccine among 115 HIV-infected patients after a preventive immunisation campaign in Mali. Trans R Soc Trop Med Hyg 2012; 106:437-44.
69. Farez MF, Correale J. Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis. Arch Neurol 2011; 68:1267-71.
70. Feldman S, Hughes WT, Daniel CB. Varicella in children with cancer: Seventy-seven cases. Pediatrics 1975; 56:388-97.
71. Lynfield R, Herrin JT, Rubin RH. Varicella in pediatric renal transplant recipients. Pediatrics 1992; 90:216-20.
72. Hambleton S. Chickenpox. Curr Opin Infect Dis 2005; 18:235-40.
73. Schrauder A, Henke-Gendo C, Seidemann K, et al. Varicella vaccination in a child with acute lymphoblastic leukaemia. Lancet 2007; 369:1232.
74. Kraft JN, Shaw JC. Varicella infection caused by Oka strain vaccine in a heart transplant recipient. Arch Dermatol 2006; 142:943-5.
75. Ngai AL, Staehle BO, Kuter BJ, et al. Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children. Pediatr Infect Dis J 1996; 15:49-54.
76. Bryan CJ, Prichard MN, Daily S, et al. Acyclovir-resistant chronic ver-rucous vaccine strain varicella in a patient with neuroblastoma. Pediatr Infect Dis J 2008; 27:946-8.
77. Levin MJ, Dahl KM, Weinberg A, Giller R, Patel A, Krause PR. Development of resistance to acyclovir during chronic infection with the Oka vaccine strain of varicella-zoster virus in an immunosuppressed child. J Infect Dis 2003; 188:954-9.
78. Gershon AA, LaRussa P, Steinberg S. The varicella vaccine. Clinical trials in immunocompromised individuals. Infect Dis Clin North Am 1996; 10:583-94.
79. Levin MJ, Gershon AA, Weinberg A, Song LY, Fentin T, Nowak B. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells. J Infect Dis 2006; 194:247-55.
80. Gershon AA, Steinberg SP, Gelb L. Live attenuated varicella vaccine use in immunocompromised children and adults. Pediatrics 1986; 78:757-62.
81. Gershon AA, Steinberg SP. Persistence of immunity to varicella in children with leukemia immunized with live attenuated varicella vaccine. N Engl J Med 1989; 320:892-7.
82. Takahashi M, Kamiya H, Baba K, Asano Y, Ozaki T, Horiuchi K. Clinical experience with Oka live varicella vaccine in Japan. Postgrad Med J 1985; 61 (Suppl 4):61-7.
83. Takahashi M. Clinical overview of varicella vaccine: development and early studies. Pediatrics 1986; 78:736-41.
84. Levin MJ. Varicella vaccination of immunocompromised children. J Infect Dis 2008; 197 (Suppl 2):S200-6.
85. Sauerbrei A, Prager J, Hengst U, Zintl F, Wutzler P. Varicella vaccination in children after bone marrow transplantation. Bone Marrow Transplant 1997; 20:381-3.
86. Small TN, Robinson WH, Miklos DB. B cells and transplantation: an educational resource. Biol Blood Marrow Transplant 2009; 15:104-13.
87. Chou JF, Kernan NA, Prockop S, et al. Safety and immunogenicity of the live attenuated varicella vaccine following T replete or T cell-depleted related and unrelated allogeneic hematopoietic cell transplantation (alloHCT). Biol Blood Marrow Transplant 2011; 17:1708-13.
88. Levin MJ, Gershon AA, Weinberg A, et al. Immunization of HIV-in-fected children with varicella vaccine. J Pediatr 2001; 139:305-10.
89. Wood SM, Shah SS, Steenhoff AP, Rutstein RM. Primary varicella and herpes zoster among HIV-infected children from 1989 to 2006. Pediatrics 2008; 121:e150-6.
90. Dowell SF, Bresee JS. Severe varicella associated with steroid use. Pediatrics 1993; 92:223-8.
91. Lydick E, Kuter BJ, Zajac BA, Guess HA. Association of steroid therapy with vaccine-associated rashes in children with acute lympho-cytic leukaemia who received Oka/Merck varicella vaccine. NIAID Varicella Vaccine Collaborative Study Group. Vaccine 1989; 7:549-53.
92. Lu Y, Bousvaros A. Varicella vaccination in children with inflammatory bowel disease receiving immunosuppressive therapy. J Pediatr Gas-troenterol Nutr 2010; 50:562-5.
93. Pileggi GS, de Souza CB, Ferriani VP. Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids. Arthritis Care Res (Hoboken) 2010; 62:1034-9.
94. Klein NP, Fireman B, Yih WK, et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics 2010; 126:e1-8.
95. Jacobsen SJ, Ackerson BK, Sy LS, et al. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine 2009; 27:4656-61.
96. Schlienger K, Lange J, Tyring S. Immunogenicity, kinetics of VZV-specific CD4 T-cell g-IFN production and safety of a live attenuated Oka/Merck zoster vaccine in healthy adults ≥60 years of age. Clin Vaccine Immunol 2009; 16: 1381-1382.
97. ®) in patients with hematologic malignancy and he-matopoietic cell transplant recipients. Am J Hematol 2012; 87:123-5.
98. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009; 301:737-44.
99. Wendling D, Streit G, Toussirot E, Prati C. Herpes zoster in patients taking TNFalpha antagonists for chronic inflammatory joint disease. Joint Bone Spine 2008; 75:540-3.
100. Del Porto F, Lagana B, Biselli R, et al. Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity. Vaccine 2006; 24:3217-23.
101. Oren S, Mandelboim M, Braun-Moscovici Y, et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis 2008; 67:937-41.
102. Fowke KR, D'Amico R, Chernoff DN, et al. Immunologic and virolog-ic evaluation after influenza vaccination of HIV-1-infected patients. AIDS 1997; 11:1013-21.
103. Edvardsson VO, Flynn JT, Deforest A, et al. Effective immunization against influenza in pediatric renal transplant recipients. Clin Transplant 1996; 10:556-60.
104. Duchini A, Hendry RM, Nyberg LM, Viernes ME, Pockros PJ. Immune response to influenza vaccine in adult liver transplant recipients. Liver Transpl 2001; 7:311-3.
105. van Assen S, Holvast A, Telgt DS, et al. Patients with humoral primary immunodeficiency do not develop protective anti-influenza antibody titers after vaccination with trivalent subunit influenza vaccine. Clin Immunol 2010; 136:228-35.
106. Levin MJ, Song LY, Fenton T, et al. Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. Vaccine 2008; 26:4210-7.
107. Carr S, Allison KJ, Van De Velde LA, et al. Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer. J Infect Dis 2011; 204:1475-82.
108. Notarangelo LD. Primary immunodeficiencies. J Allergy Clin Immunol 2010; 125:S182-94.
109. No authors listed. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61:816-9.
110. Andreoni J, Kayhty H, Densen P. Vaccination and the role of capsular polysaccharide antibody in prevention of recurrent meningococcal disease in late complement component-deficient individuals. J Infect Dis 1993; 168:227-31.
111. Biselli R, Casapollo I, D'Amelio R, Salvato S, Matricardi PM, Brai M. Antibody response to meningococcal polysaccharides A and C in patients with complement defects. Scand J Immunol 1993; 37:644-50.
112. Drogari-Apiranthitou M, Fijen CA, Van De Beek D, Hensen EF, Dankert J, Kuijper EJ. Development of antibodies against tetravalent meningococcal polysaccharides in revaccinated complement-deficient patients. Clin Exp Immunol 2000; 119:311-6.
113. Fijen CA, Kuijper EJ, Drogari-Apiranthitou M, Van Leeuwen Y, Daha MRDankert J. Protection against meningococcal serogroup ACYW disease in complement-deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine. Clin Exp Immunol 1998; 114:362-9.
114. Platonov AE, Beloborodov VB, Pavlova LI, Vershinina IV, Kayhty H. Vaccination of patients deficient in a late complement component with tetravalent meningococcal capsular polysaccharide vaccine. Clin Exp Immunol 1995; 100:32-9.
115. Platonov AE, Vershinina IV, Kuijper EJ, Borrow R, Kayhty H. Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine. Vaccine 2003; 21:4437-47.
116. Soderstrom C, Braconier JH, Kayhty H, Sjoholm AG, Thuresson B. Immune response to tetravalent meningococcal vaccine: opsonic and bactericidal functions of normal and properdin deficient sera. Eur J Clin Microbiol Infect Dis 1989; 8:220-4.
117. No authors listed. Infant meningococcal vaccination: Advisory Committee on Immunization Practices (ACIP) recommendations and rationale. MMWR Morb Mortal Wkly Rep 2013; 62:52-4.
118. Vu DM, Welsch JA, Zuno-Mitchell P, Dela Cruz JV, Granoff DM. Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine. J Infect Dis 2006; 193:821-8.
119. Gill CJ, Baxter R, Anemona A, Ciavarro G, Dull P. Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo) or Menactra among healthy adolescents. Hum Vaccin 2010; 6:881-7.
120. Attwood JT, Williams Y, Feighery C. Impaired IgG responses in a child with homozygous C2 deficiency and recurrent pneumococcal septicaemia. Acta Paediatr 2001; 90:99-101.
121. Berkel AI. Studies of immune response in a patient with selective complete C1q deficiency. Turk J Pediatr 1993; 35:221-6.
122. Hohler T, Stradmann-Bellinghausen B, Starke R, et al. C4A deficiency and nonresponse to hepatitis B vaccination. J Hepatol 2002; 37:387-92.
123. Jackson CG, Ochs HD, Wedgwood RJ. Immune response of a patient with deficiency of the fourth component of complement and systemic lupus erythematosus. N Engl J Med 1979; 300:1124-9.
124. No authors listed. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children-Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2010; 59:258-61.
125. Walter ND, Taylor TH, Shay DK, et al. Influenza circulation and the burden of invasive pneumococcal pneumonia during a non-pandemic period in the United States. Clin Infect Dis 2010; 50:175-83.
126. Jansen AG, Sanders EA, Van Der Ende A, Van Loon AM, Hoes AW, Hak E. Invasive pneumococcal and meningococcal disease: association with influenza virus and respiratory syncytial virus activity? Epidemiol Infect 2008; 136:1448-54.
127. Winkelstein JA, Marino MC, Johnston RB Jr., et al. Chronic granulo-matous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000; 79:155-69.
128. van den Berg JM, van Koppen E, Ahlin A, et al. Chronic granuloma-tous disease: the European experience. PLoS One 2009; 4:e5234.
129. Finelli L, Fiore A, Dhara R, et al. Influenza-associated pediatric mortality in the United States: increase of Staphylococcus aureus coinfec-tion. Pediatrics 2008; 122:805-11.
130. Voss LM, Abraham RT, Rhodes KH, Schoon RA, Leibson PJ. Defective T-lymphocyte signal transduction and function in leukocyte adhesion deficiency. J Clin Immunol 1991; 11:175-83.
131. Baetz K, Isaaz S, Griffiths GM. Loss of cytotoxic T lymphocyte function in Chediak-Higashi syndrome arises from a secretory defect that prevents lytic granule exocytosis. J Immunol 1995; 154:6122-31.
132. Kobayashi Y, Komazawa Y, Kobayashi M, et al. Presumed BCG infection in a boy with chronic granulomatous disease. A report of a case and a review of the literature. Clin Pediatr (Phila) 1984; 23:586-9.
133. Smith PA, Wittenberg DF. Disseminated BCG infection in a child with chronic granulomatous disease. A case report. S Afr Med J 1984; 65:821-2.
134. Kawashima H, Hasegawa D, Nakamura M, et al. Hazards of early BCG vaccination: BCGitis in a patient with chronic granulomatous disease. Pediatr Int 2007; 49:418-9.
135. Kusuhara K, Ohga S, Hoshina T, et al. Disseminated bacillus Calm-ette-Guerin lymphadenitis in a patient with gp91phox-chronic granu-lomatous disease 25 years after vaccination. Eur J Pediatr 2009; 168:745-7.
136. Mansouri D, Adimi P, Mirsaeidi M, et al. Inherited disorders of the IL-12-IFN-gamma axis in patients with disseminated BCG infection. Eur J Pediatr 2005; 164:753-7.
137. Dai YS, Liang MG, Gellis SE, et al. Characteristics of mycobacterial infection in patients with immunodeficiency and nuclear factor-kappaB essential modulator mutation, with or without ectodermal dysplasia. J Am Acad Dermatol 2004; 51:718-22.
138. Orange JS, Jain A, Ballas ZK, Schneider LC, Geha RS, Bonilla FA. The presentation and natural history of immunodeficiency caused by nuclear factor kappaB essential modulator mutation. J Allergy Clin Immunol 2004; 113:725-33.
139. Pasic S, Lilic D, Pejnovic N, Vojvodic D, Simic R, Abinun M. Disseminated bacillus Calmette-Guerin infection in a girl with hyperimmuno-globulin E syndrome. Acta Paediatr 1998; 87:702-4.
140. Pasic S. Local bacillus Calmette-Guerin infection in hyperimmunoglo- bulin-E syndrome. Acta Paediatr 2002; 91:1271-2.
141. Zhang SY, Boisson-Dupuis S, Chapgier A, et al. Inborn errors of inter-feron (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense. Immunol Rev 2008; 226:29-40.
142. Dupuis S, Jouanguy E, Al-Hajjar S, et al. Impaired response to inter-feron-alpha/beta and lethal viral disease in human STAT1 deficiency. Nat Genet 2003; 33:388-91.
143. Schubert MS, Moss RB. Selective polysaccharide antibody deficiency in familial DiGeorge syndrome. Ann Allergy 1992; 69:231-8.
144. Gennery AR, Barge D, O'Sullivan JJ, Flood TJ, Abinun M, Cant AJ. Antibody deficiency and autoimmunity in 22q11.2 deletion syndrome. Arch Dis Child 2002; 86:422-5.
145. Kirkpatrick CH. Specific polysaccharide antibody deficiency. Ann Allergy Asthma Immunol 2006; 97:271.
146. Shrimpton A, Duddridge M, Ziegler-Heitbrock L. Vaccination with polysaccharide-conjugate-vaccines in adult patients with specific antibody deficiency. Vaccine 2006; 24:3574-80.
147. Schubert R, Reichenbach J, Rose M, Zielen S. Immunogenicity of the seven valent pneumococcal conjugate vaccine in patients with ataxia-telangiectasia. Pediatr Infect Dis J 2004; 23:269-70.
148. Sanal O, Ersoy F, Tezcan I, et al. Antibody response to a seven-valent pneumococcal conjugated vaccine in patients with ataxia-telangiecta-sia. J Clin Immunol 2004; 24:411-7.
149. Stray-Pedersen A, Aaberge IS, Fruh A, Abrahamsen TG. Pneumococ-cal conjugate vaccine followed by pneumococcal polysaccharide vaccine; immunogenicity in patients with ataxia-telangiectasia. Clin Exp Immunol 2005; 140:507-16.
150. Asindi AA, Bell EJ, Browning MJ, Stephenson JB. Vaccine-induced polioencephalomyelitis in Scotland. Scott Med J 1988; 33:306-7.
151. Inaba H, Hori H, Ito M, et al. Polio vaccine virus-associated meningo-encephalitis in an infant with transient hypogammaglobulinemia. Scand J Infect Dis 2001; 33:630-1.
152. Martin J. Vaccine-derived poliovirus from long term excretors and the end game of polio eradication. Biologicals 2006; 34:117-22.
153. Rezaei N, Aghamohammadi A, Read RC. Response to polysaccharide vaccination amongst pediatric patients with common variable immunodeficiency correlates with clinical disease. Iran J Allergy Asthma Immunol 2008; 7:231-4.
154. Goldacker S, Draeger R, Warnatz K, et al. Active vaccination in patients with common variable immunodeficiency (CVID). Clin Immunol 2007; 124:294-303.
155. Rezaei N, Siadat SD, Aghamohammadi A, et al. Serum bactericidal antibody response 1 year after meningococcal polysaccharide vaccination of patients with common variable immunodeficiency. Clin Vaccine Immunol 2010; 17:524-8.
156. Hidalgo S, Garcia Erro M, Cisterna D, Freire MC. Paralytic poliomyelitis caused by a vaccine-derived polio virus in an antibody-deficient Argentinean child. Pediatr Infect Dis J 2003; 22:570-2.
157. Misbah SA, Lawrence PA, Kurtz JB, Chapel HM. Prolonged faecal excretion of poliovirus in a nurse with common variable hypogamma-globulinaemia. Postgrad Med J 1991; 67:301-3.
158. Shahmahmoodi S, Parvaneh N, Burns C, et al. Isolation of a type 3 vaccine-derived poliovirus (VDPV) from an Iranian child with X-linked agammaglobulinemia. Virus Res 2008; 137:168-72.
159. Fiore L, Plebani A, Buttinelli G, et al. Search for poliovirus long-term ex-cretors among patients affected by agammaglobulinemia. Clin Immunol 2004; 111:98-102.
160. Halsey NA, Pinto J, Espinosa-Rosales F, et al. Search for poliovirus carriers among people with primary immune deficiency diseases in the United States, Mexico, Brazil, and the United Kingdom. Bull World Health Organ 2004; 82:3-8.
161. Werther RL, Crawford NW, Boniface K, Kirkwood CD, Smart JM. Ro-tavirus vaccine induced diarrhea in a child with severe combined immune deficiency. J Allergy Clin Immunol 2009; 124:600.
162. Patel NC, Hertel PM, Estes MK, et al. Vaccine-acquired rotavirus in infants with severe combined immunodeficiency. N Engl J Med 2010; 362:314-9.
163. Uygungil B, Bleesing JJ, Risma KA, McNeal MM, Rothenberg ME. Persistent rotavirus vaccine shedding in a new case of severe combined immunodeficiency: A reason to screen. J Allergy Clin Immunol 2010; 125:270-1.
164. Azzari C, Gambineri E, Resti M, et al. Safety and immunogenicity of measles-mumps-rubella vaccine in children with congenital immunodeficiency (DiGeorge syndrome). Vaccine 2005; 23: 1668-71.
165. Moylett EH, Wasan AN, Noroski LM, Shearer WT. Live viral vaccines in patients with partial DiGeorge syndrome: clinical experience and cellular immunity. Clin Immunol 2004; 112:106-12.
166. Perez EE, Bokszczanin A, McDonald-McGinn D, Zackai EH, Sullivan KE. Safety of live viral vaccines in patients with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Pediatrics 2003; 112:e325.
167. Al-Sukaiti N, Reid B, Lavi S, et al. Safety and efficacy of measles, mumps, and rubella vaccine in patients with DiGeorge syndrome. J Allergy Clin Immunol 2010; 126:868-9.
168. Ermolovich MA, Fel'dman EV, Samoilovich EO, Kuzovkova NA, Levin VI. Characterization of the immune status of patients with vaccine-associated poliomyelitis. Zh Mikrobiol Epidemiol Immuno-biol 2002:42-50.
169. Mihatsch MJ, Ohnacker H, Just M, Nars PW. Lethal measles giant cell pneumonia after live measles vaccination in a case of thymic alympho-plasia Gitlin. Helv Paediatr Acta 1972; 27:143-6.
170. Monafo WJ, Haslam DB, Roberts RL, Zaki SR, Bellini WJ, Coffin CM. Disseminated measles infection after vaccination in a child with a congenital immunodeficiency. J Pediatr 1994; 124:273-6.
171. Schuil J, van de Putte EM, Zwaan CM, Koole FD, Meire FM. Retinop-athy following measles, mumps, and rubella vaccination in an immuno-incompetent girl. Int Ophthalmol 1998; 22:345-7.
172. Bakare N, Menschik D, Tiernan R, Hua W, Martin D. Severe combined immunodeficiency (SCID) and rotavirus vaccination: reports to the Vaccine Adverse Events Reporting System (VAERS). Vaccine 2010; 28:6609-12.
173. Egeler RM, Shapiro R, Loechelt B, Filipovich A. Characteristic immune abnormalities in hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol 1996; 18:340-5.
174. Yeganeh M, Heidarzade M, Pourpak Z, et al. Severe combined immunodeficiency: a cohort of 40 patients. Pediatr Allergy Immunol 2008; 19:303-6.
175. Donovan RM, Moore E, Bush CE, Markowitz NP, Saravolatz LD. Changes in plasma HIV RNA levels and CD4 cell counts after vaccination of pediatric patients. AIDS 1997; 11:1054-6.
176. Calmy A, Bel M, Nguyen A, et al. Strong serological responses and HIV RNA increase following AS03-adjuvanted pandemic immunization in HIV-infected patients. HIV Med 2012; 13:207-18.
177. Weinberg A, Gona P, Nachman SA, et al. Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immu-nologic reconstitution while receiving highly active antiretroviral therapy. J Infect Dis 2006; 193:302-11.
178. Abzug MJ, Pelton SI, Song LY, et al. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J 2006; 25:920-9.
179. Abzug MJ, Song LY, Fenton T, et al. Pertussis booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. Pediatrics 2007; 120:e1190-202.
180. Levin MJ, Moscicki AB, Song LY, et al. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr 2010:197-204.
181. Weinberg A, Song LY, Fenton T, et al. T cell responses of HIV-infected children after administration of inactivated or live attenuated influenza vaccines. AIDS Res Hum Retroviruses 2010; 26:51-9.
182. Madhi SA, Kuwanda L, Saarinen L, et al. Immunogenicity and effectiveness of Haemophilus influenzae type b conjugate vaccine in HIV infected and uninfected African children. Vaccine 2005; 23:5517-25.
183. Tedaldi EM, Baker RK, Moorman AC, et al. Hepatitis A and B vaccination practices for ambulatory patients infected with HIV. Clin Infect Dis 2004; 38:1478-84.
184. Sutcliffe CG, Moss WJ. Do children infected with HIV receiving HAART need to be revaccinated? Lancet Infect Dis 2010; 10:630-42.
185. Miotti PG, Nelson KE, Dallabetta GA, Farzadegan H, Margolick J, Clements ML. The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine. JAMA 1989; 262:779-83.
186. Chadwick EG, Chang G, Decker MD, Yogev R, Dimichele D, Edwards KM. Serologic response to standard inactivated influenza vaccine in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1994; 13:206-11.
187. Kroon FP, van Dissel JT, de Jong JC, van Furth R. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes. AIDS 1994; 8:469-76.
188. Vigano A, Zuccotti GV, Pacei M, et al. Humoral and cellular response to influenza vaccine in HIV-infected children with full viroimmuno-logic response to antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 48:289-96.
189. Madhi SA, Maskew M, Koen A, et al. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis 2011; 52:128-37.
190. O'Brien WA, Grovit-Ferbas K, Namazi A, et al. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 1995; 86:1082-9.
191. Rosok B, Voltersvik P, Bjerknes R, Axelsson M, Haaheim LR, Asjo B. Dynamics of HIV-1 replication following influenza vaccination of HIV+ individuals. Clin Exp Immunol 1996; 104:203-7.
192. Glesby MJ, Hoover DR, Farzadegan H, Margolick JB, Saah AJ. The effect of influenza vaccination on human immunodeficiency virus type 1 load: a randomized, double-blind, placebo-controlled study. J Infect Dis 1996; 174:1332-6.
193. Tasker SA, O'Brien WA, Treanor JJ, et al. Effects of influenza vaccination in HIV-infected adults: a double-blind, placebo-controlled trial. Vaccine 1998; 16:1039-42.
194. Crum-Cianflone NF, Eberly LE, Duplessis C, et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocom-promised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis 2011; 52:138-46.
195. Flynn P, Nachman S, Spector SA. H1N1 immunization in HIV-1 peri-natally infected children and youth. J Infect Dis. 2012; 206:421-30.
196. Madhi SA, Adrian P, Kuwanda L, et al. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine 2007; 25:2451-7.
197. Dworkin MS, Ward JW, Hanson DL, Jones JL, Kaplan JE. Pneumo-coccal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin Infect Dis 2001; 32:794-800.
198. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003; 349:1341-8.
199. Nachman S, Kim S, King J, et al. Safety and immunogenicity of a hep-tavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection. Pediatrics 2003; 112:66-73.
200. Arpadi SM, Back S, O'Brien J, Janoff EN. Antibodies to pneumococcal capsular polysaccharides in children with human immunodeficiency virus infection given polyvalent pneumococcal vaccine. J Pediatr 1994; 125:77-9.
201. King JC Jr., Vink PE, Farley JJ, et al. Comparison of the safety and im-munogenicity of a pneumococcal conjugate with a licensed polysac-charide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children. Pediatr Infect Dis J 1996; 15:192-6.
202. Tangsinmankong N, Kamchaisatian W, Day NK, Sleasman JW, Emmanuel PJ. Immunogenicity of 23-valent pneumococcal polysaccha-ride vaccine in children with human immunodeficiency virus undergoing highly active antiretroviral therapy. Ann Allergy Asthma Immunol 2004; 92:558-64.
203. Madhi SA, Klugman KP, Kuwanda L, Cutland C, Kayhty H, Adrian P. Quantitative and qualitative anamnestic immune responses to pneu-mococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 years after vaccination. J Infect Dis 2009; 199:1168-76.
204. Lesprit P, Pedrono G, Molina JM, et al. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS 2007; 21:2425-34.
205. French N, Gordon SB, Mwalukomo T, et al. A trial of a 7-valent pneu-mococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010; 362:812-22.
206. Hung CC, Chen MY, Hsieh SM, Hsiao CF, Sheng WH, Chang SC. Clinical experience of the 23-valent capsular polysaccharide pneumo-coccal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study. Vaccine 2004; 22:2006-12.
207. Grau I, Pallares R, Tubau F, et al. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Intern Med 2005; 165:1533-40.
208. Watera C, Nakiyingi J, Miiro G, et al. 23-valent pneumococcal poly-saccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort. AIDS 2004; 18:1210-3.
209. French N, Nakiyingi J, Carpenter LM, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000; 355:2106-11.
210. Gibb D, Giacomelli A, Masters J, et al. Persistence of antibody responses to Haemophilus influenzae type b polysaccharide conjugate vaccine in children with vertically acquired human immunodeficiency virus infection. Pediatr Infect Dis J 1996; 15:1097-101.
211. Madhi SA, Petersen K, Khoosal M, et al. Reduced effectiveness of Hae-mophilus influenzae type b conjugate vaccine in children with a high prevalence of human immunodeficiency virus type 1 infection. Pediatr Infect Dis J 2002; 21:315-21.
212. Daza P, Banda R, Misoya K, et al. The impact of routine infant immunization with Haemophilus influenzae type b conjugate vaccine in Malawi, a country with high human immunodeficiency virus prevalence. Vaccine 2006; 24:6232-9.
213. Borrow R, Southern J, Andrews N, et al. Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naive controls. Vaccine 2001; 19:3043-50.
214. Richmond P, Kaczmarski E, Borrow R, et al. Meningococcal C poly-saccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis 2000; 181:761-4.
215. Siberry GK, Williams PL, Lujan-Zilbermann J, et al. Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents. Pediatr Infect Dis J 2010; 29:391-6.
216. Siberry GK, Warshaw MG, Williams PL, et al. Safety and immunoge-nicity of quadrivalent meningococcal conjugate vaccine in 2-to 10-year-old human immunodeficiency virus-infected children. Pediatr Infect Dis J 2012; 31:47-52.
217. de Martino M, Podda A, Galli L, et al. Acellular pertussis vaccine in children with perinatal human immunodeficiency virus-type 1 infection. Vaccine 1997; 15:1235-8.
218. Farquhar C, Wamalwa D, Selig S, et al. Immune responses to measles and tetanus vaccines among Kenyan human immunodeficiency virus type 1 (HIV-1)-infected children pre-and post-highly active antiretro-viral therapy and revaccination. Pediatr Infect Dis J 2009; 28:295-9.
219. Melvin AJ, Mohan KM. Response to immunization with measles, tetanus, and Haemophilus influenzae type b vaccines in children who have human immunodeficiency virus type 1 infection and are treated with highly active antiretroviral therapy. Pediatrics 2003; 111:e641-4.
220. Rosenblatt HM, Song LY, Nachman SA, et al. Tetanus immunity after diphtheria, tetanus toxoids, and acellular pertussis vaccination in children with clinically stable HIV infection. J Allergy Clin Immunol 2005; 116:698-703.
221. Tovo PA, de Martino M, Gabiano C, Galli L. Pertussis immunization in HIV-1-infected infants: a model to assess the effects of repeated T cell-dependent antigen administrations on HIV-1 progression. Italian Register for HIV infection in children. Vaccine 2000; 18:1203-9.
222. Xu WM, Cui YT, Wang L, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multi-centre, randomized, double-blind, placebo-controlled study. J Viral Hepat 2009; 16:94-103.
223. Pickering LK, Baker CJ, Kimberlin DW, Long SS. Red Book: 2012 report of the Committee on Infectious Diseases. 29 ed. Elk Grove Village: American Academy of Pediatrics, 2012.
224. Collier AC, Corey L, Murphy VL, Handsfield HH. Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. Ann Intern Med 1988; 109:101-5.
225. Pasricha N, Datta U, Chawla Y, et al. Immune responses in patients with HIV infection after vaccination with recombinant hepatitis B virus vaccine. BMC Infect Dis 2006; 6:65.
226. Veiga AP, Casseb J, Duarte AJ. Humoral response to hepatitis B vaccination and its relationship with T CD45RA+ (naive) and CD45RO+ (memory) subsets in HIV-1-infected subjects. Vaccine 2006; 24:7124-8.
227. Cornejo-Juarez P, Volkow-Fernandez P, Escobedo-Lopez K, Vilar-Compte D, Ruiz-Palacios G, Soto-Ramirez LE. Randomized controlled trial of hepatitis B virus vaccine in HIV-1-infected patients comparing two different doses. AIDS Res Ther 2006; 3:9.
228. Kim HN, Harrington RD, Van Rompaey SE, Kitahata MM. Independent clinical predictors of impaired response to hepatitis B vaccination in HIV-infected persons. Int J STD AIDS 2008; 19:600-4.
229. Keet IP, van Doornum G, Safary A, Coutinho RA. Insufficient response to hepatitis B vaccination in HIV-positive homosexual men. AIDS 1992; 6:509-10.
230. Abzug MJ, Warshaw M, Rosenblatt HM, et al. Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis 2009; 200:935-46.
231. Laurence JC. Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. Am J Med 2005; 118 (Suppl 10A):75S-83.
232. Overton ET, Sungkanuparph S, Powderly WG, Seyfried W, Groger RKAberg JA. Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis 2005; 41:1045-8.
233. Cruciani M, Mengoli C, Serpelloni G, et al. Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients. Vaccine 2009; 27:17-22.
234. Zuin G, Principi N, Tornaghi R, et al. Impaired response to hepatitis B vaccine in HIV infected children. Vaccine 1992; 10:857-60.
235. Irungu E, Mugo N, Ngure K, et al. Immune response to hepatitis B virus vaccination among HIV-1 infected and uninfected adults in Kenya. J Infect Dis 2013; 207:402-10.
236. Rey D, Krantz V, Partisani M, et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine 2000; 18:1161-5.
237. Scolfaro C, Fiammengo P, Balbo L, Madon E, Tovo PA. Hepatitis B vaccination in HIV-1-infected children: double efficacy doubling the paediatric dose. AIDS 1996; 10:1169-70.
238. Flynn M, Kort R. XVII International AIDS Conference: From Evidence to Action-Epidemiology. J Int AIDS Soc 2009; 12 (Suppl 1):S2.
239. Lao-Araya M, Puthanakit T, Aurpibul L, Taecharoenkul S, Sirisantha-na T, Sirisanthana V. Prevalence of protective level of hepatitis B antibody 3 years after revaccination in HIV-infected children on antiretroviral therapy. Vaccine 2011; 29:3977-81.
240. Poovorawan Y, Chongsrisawat V, Theamboonlers A, et al. Long-term benefit of hepatitis B vaccination among children in Thailand with transient hepatitis B virus infection who were born to hepatitis B surface antigen-positive mothers. J Infect Dis 2009; 200:33-8.
241. Jongjirawisan Y, Ungulkraiwit P, Sungkanuparph S. Isolated antibody to hepatitis B core antigen in HIV-1 infected patients and a pilot study of vaccination to determine the anamnestic response. J Med Assoc Thai 2006; 89:2028-34.
242. Gandhi RT, Wurcel A, McGovern B, et al. Low prevalence of ongoing hepatitis B viremia in HIV-positive individuals with isolated antibody to hepatitis B core antigen. J Acquir Immune Defic Syndr 2003; 34:439-41.
243. Kemper CA, Haubrich R, Frank I, et al. Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: a double-blind, randomized, placebo-controlled trial. J Infect Dis 2003; 187:1327-31.
244. Wallace MR, Brandt CJ, Earhart KC, et al. Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects. Clin Infect Dis 2004; 39:1207-13.
245. Sudjaritruk T, Sirisanthana T, Sirisanthana V. Antibody responses to hepatitis A virus vaccination in Thai HIV-infected children with immune recovery after antiretroviral therapy. Pediatr Infect Dis J 2011; 30:256-9.
246. Crum-Cianflone NF, Wilkins K, Lee AW, et al. Long-term durability of immune responses after hepatitis A vaccination among HIV-infect-ed adults. J Infect Dis 2011; 203:1815-23.
247. Barbi M, Biffi MR, Binda S, et al. Immunization in children with HIV seropositivity at birth: antibody response to polio vaccine and tetanus toxoid. AIDS 1992; 6:1465-9.
248. Kroon FP, van Dissel JT, Labadie J, van Loon AM, van Furth R. Antibody response to diphtheria, tetanus, and poliomyelitis vaccines in relation to the number of CD4+ T lymphocytes in adults infected with human immunodeficiency virus. Clin Infect Dis 1995; 21:1197-203.
249. Wilkin T, Lee JY, Lensing SY, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis 2010; 202:1246-53.
250. Palefsky JM, Holly EA, Ralston ML, Jay N, Berry JM, Darragh TM. High incidence of anal high-grade squamous intra-epithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men. AIDS 1998; 12:495-503.
251. Cortese MM, Parashar UD. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2009; 58:1-25.
252. Madhi SA, Cunliffe NA, Steele D, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010; 362:289-98.
253. Steele AD, Madhi SA, Louw CE, et al. Safety, Reactogenicity, and im-munogenicity of human rotavirus vaccine RIX4414 in human immunodeficiency virus-positive infants in South Africa. Pediatr Infect Dis J 2011; 30:125-30.
254. Palumbo P, Hoyt L, Demasio K, Oleske J, Connor E. Population-based study of measles and measles immunization in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1992; 11:1008-14.
255. Aurpibul L, Puthanakit T, Siriaksorn S, Sirisanthana T, Sirisanthana V. Prevalence of protective antibody against measles in HIV-infected children with immune recovery after highly active antiretroviral therapy. HIV Med 2006; 7:467-70.
256. Bekker V, Scherpbier H, Pajkrt D, Jurriaans S, Zaaijer H, Kuijpers TW. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection. Pediatrics 2006; 118:e315-22.
257. Berkelhamer S, Borock E, Elsen C, Englund J, Johnson D. Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunodeficiency virus-infected children. Clin Infect Dis 2001; 32:1090-4.
258. Brena AE, Cooper ER, Cabral HJ, Pelton SI. Antibody response to measles and rubella vaccine by children with HIV infection. J Acquir Immune Defic Syndr 1993; 6:1125-9.
259. Lima M, De Menezes Succi RC, Nunes Dos Santos AM, Weckx LY, De Moraes-Pinto MI. Rubella immunization in human immunodeficiency virus type 1-infected children: cause for concern in vaccination strategies. Pediatr Infect Dis J 2004; 23:604-7.
260. Aurpibul L, Puthanakit T, Sirisanthana T, Sirisanthana V. Response to measles, mumps, and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. Clin Infect Dis 2007; 45:637-42.
261. Scott P, Moss WJ, Gilani Z, Low N. Measles vaccination in HIV-in-fected children: systematic review and meta-analysis of safety and im-munogenicity. J Infect Dis 2011; 204 (Suppl 1):S164-78.
262. No authors listed. Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection 1993. MMWR Morb Mortal Wkly Rep 1996; 45: 603-6.
263. Sprauer MA, Markowitz LE, Nicholson JK, et al. Response of human immunodeficiency virus-infected adults to measles-rubella vaccination. J Acquir Immune Defic Syndr 1993; 6:1013-6.
264. Goyal S, Pai SK, Kelkar R, Advani SH. Hepatitis B vaccination in acute lymphoblastic leukemia. Leuk Res 1998; 22:193-5.
265. Yu JW, Borkowski A, Danzig L, Reiter S, Kavan P, Mazer BD. Immune response to conjugated meningococcal C vaccine in pediatric oncology patients. Pediatr Blood Cancer 2007; 49:918-23.
266. Ercan TE, Soycan LY, Apak H, et al. Antibody titers and immune response to diphtheria-tetanus-pertussis and measles-mumps-rubella vaccination in children treated for acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2005; 27:273-7.
267. Polychronopoulou-Androulakaki S, Panagiotou JP, Kostaridou S, Kyr-atzopoulou A, Haidas S. Immune response of immunocompromised children with malignancies to a recombinant hepatitis B vaccine. Pediatr Hematol Oncol 1996; 13:425-31.
268. Rokicka-Milewska R, Jackowska T, Sopylo B, Kacperska E, Seyfried H. Active immunization of children with leukemias and lymphomas against infection by hepatitis B virus. Acta Paediatr Jpn 1993; 35:400-3.
269. Zengin E, Sarper N. Humoral immunity to diphtheria, tetanus, measles, and hemophilus influenzae type b in children with acute lym-phoblastic leukemia and response to re-vaccination. Pediatr Blood Cancer 2009; 53:967-72.
270. Patel SR, Ortin M, Cohen BJ, et al. Revaccination of children after completion of standard chemotherapy for acute leukemia. Clin Infect Dis 2007; 44:635-42.
271. Alanko S, Pelliniemi TT, Salmi TT. Recovery of blood B-lymphocytes and serum immunoglobulins after chemotherapy for childhood acute lymphoblastic leukemia. Cancer 1992; 69:1481-6.
272. Alanko S, Salmi TT, Pelliniemi TT. Recovery of blood T-cell subsets after chemotherapy for childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 1994; 11:281-92.
273. Alanko S, Salmi TT, Pelliniemi TT. Recovery of natural killer cells after chemotherapy for childhood acute lymphoblastic leukemia and solid tumors. Med Pediatr Oncol 1995; 24:373-8.
274. Mustafa MM, Buchanan GR, Winick NJ, et al. Immune recovery in children with malignancy after cessation of chemotherapy. J Pediatr Hematol Oncol 1998; 20:451-7.
275. Pao M, Papadopoulos EB, Chou J, et al. Response to pneumococcal (PNCRM7) and haemophilus influenzae conjugate vaccines (HIB) in pediatric and adult recipients of an allogeneic hematopoietic cell transplantation (alloHCT). Biol Blood Marrow Transplant 2008; 14:1022-30.
276. Ljungman P, Andersson J, Aschan J, et al. Influenza A in immuno-compromised patients. Clin Infect Dis 1993; 17:244-7.
277. Earle CC. Influenza vaccination in elderly patients with advanced co-lorectal cancer. J Clin Oncol 2003; 21:1161-6.
278. Robertson JD, Nagesh K, Jowitt SN, et al. Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus in-fluenzae type B in patients with multiple myeloma. Br J Cancer 2000; 82:1261-5.
279. Nordoy T, Husebekk A, Aaberge IS, et al. Humoral immunity to viral and bacterial antigens in lymphoma patients 4-10 years after high-dose therapy with ABMT. Serological responses to revaccinations according to EBMT guidelines. Bone Marrow Transplant 2001; 28:681-7.
280. Nordoy T, Kolstad A, Tuck MK, Aaberge IS, Husebekk A, Kaminski MS. Radioimmunotherapy with iodine-131 tositumomab in patients with low-grade non-Hodgkin's B-cell lymphoma does not induce loss of acquired humoral immunity against common antigens. Clin Immunol 2001; 100:40-8.
281. Mazza JJ, Yale SH, Arrowood JR, et al. Efficacy of the influenza vaccine in patients with malignant lymphoma. Clin Med Res 2005; 3:214-20.
282. Centkowski P, Brydak L, Machala M, et al. Immunogenicity of influenza vaccination in patients with non-Hodgkin lymphoma. J Clin Immunol 2007; 27:339-46.
283. Lo W, Whimbey E, Elting L, Couch R, Cabanillas F, Bodey G. Antibody response to a two-dose influenza vaccine regimen in adult lym-phoma patients on chemotherapy. Eur J Clin Microbiol Infect Dis 1993; 12:778-82.
284. Yri OE, Torfoss D, Hungnes O, et al. Rituximab blocks protective se-rological response to influenza A(H1N1) 2009 vaccination in lympho-ma patients during or within six months after treatment. Blood 2011; 122:1946-53.
285. Bedognetti D, Zoppoli G, Massucco C, et al. Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens. J Immunol 2011; 186:6044-55.
286. Elting LS, Whimbey E, Lo W, Couch R, Andreeff M, Bodey GP. Epidemiology of influenza A virus infection in patients with acute or chronic leukemia. Support Care Cancer 1995; 3:198-202.
287. Anderson H, Petrie K, Berrisford C, Charlett A, Thatcher N, Zambon M. Seroconversion after influenza vaccination in patients with lung cancer. Br J Cancer 1999; 80:219-20.
288. Brydak LB, Guzy J, Starzyk J, Machala M, Gozdz SS. Humoral immune response after vaccination against influenza in patients with breast cancer. Support Care Cancer 2001; 9:65-8.
289. Meerveld-Eggink A, de Weerdt O, van der Velden AM, et al. Response to influenza virus vaccination during chemotherapy in patients with breast cancer. Ann Oncol 2011; 22:2031-5.
290. Nordoy T, Aaberge IS, Husebekk A, et al. Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae. Med Oncol 2002; 19:71-8.
291. Vilar-Compte D, Cornejo P, Valle-Salinas A, et al. Influenza vaccination in patients with breast cancer: a case-series analysis. Med Sci Monit 2006; 12:CR332-6.
292. Avritscher EB, Cooksley CD, Geraci JM, et al. Cost-effectiveness of influenza vaccination in working-age cancer patients. Cancer 2007; 109:2357-64.
293. Levine AM, Overturf GD, Field RF, Holdorf D, Paganini-Hill A, Fein-stein DI. Use and efficacy of pneumococcal vaccine in patients with Hodgkin disease. Blood 1979; 54:1171-5.
294. Siber GR, Weitzman SA, Aisenberg AC, Weinstein HJ, Schiffman G. Impaired antibody response to pneumococcal vaccine after treatment for Hodgkin's disease. N Engl J Med 1978; 299:442-8.
295. Addiego JE Jr., Ammann AJ, Schiffman G, Baehner R, Higgins G, Hammond D. Response to pneumococcal polysaccharide vaccine in patients with untreated Hodgkin's disease. Children's Cancer Study Group Report. Lancet 1980; 2:450-2.
296. Frederiksen B, Specht L, Henrichsen J, Pedersen FK, Pedersen-Bjer-gaard J. Antibody response to pneumococcal vaccine in patients with early stage Hodgkin's disease. Eur J Haematol 1989; 43:45-9.
297. Grimfors G, Soderqvist M, Holm G, Lefvert AK, Bjorkholm M. A longitudinal study of class and subclass antibody response to pneumococ-cal vaccination in splenectomized individuals with special reference to patients with Hodgkin's disease. Eur J Haematol 1990; 45:101-8.
298. Landgren O, Bjorkholm M, Konradsen HB, et al. A prospective study on antibody response to repeated vaccinations with pneumococcal capsular polysaccharide in splenectomized individuals with special reference to Hodgkin's lymphoma. J Intern Med 2004; 255:664-73.
299. Cherif H, Landgren O, Konradsen HB, Kalin M, Bjorkholm M. Poor antibody response to pneumococcal polysaccharide vaccination suggests increased susceptibility to pneumococcal infection in splenecto-mized patients with hematological diseases. Vaccine 2006; 24:75-81.
300. Molrine DC, George S, Tarbell N, et al. Antibody responses to poly-saccharide and polysaccharide-conjugate vaccines after treatment of Hodgkin disease. Ann Intern Med 1995; 123:828-34.
301. Sinisalo M, Vilpo J, Itala M, Vakevainen M, Taurio J, Aittoniemi J. Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukaemia. Vaccine 2007; 26:82-7.
302. Chan CY, Molrine DC, George S, et al. Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococ-cal vaccine after treatment of Hodgkin's disease. J Infect Dis 1996; 173:256-8.
303. Ammann AJ, Schiffman G, Addiego JE, Wara WM, Wara DW. Immunization of immunosuppressed patients with pneumococcal polysac-charide vaccine. Rev Infect Dis 1981; 3 (Suppl):S160-7.
304. Hammarstrom V, Pauksen K, Bjorkstrand B, Simonsson B, Oberg G, Ljungman P. Tetanus immunity in autologous bone marrow and blood stem cell transplant recipients. Bone Marrow Transplant 1998; 22:67-71.
305. Chung SM, Sohn JH, Kim TY, et al. Fulminant hepatic failure with hepatitis B virus reactivation after rituximab treatment in a patient with resolved hepatitis B. Korean J Gastroenterol 2010; 55:266-9.
306. Yagci M, Acar K, Sucak GT, Yamac K, Haznedar R. Hepatitis B virus vaccine in lymphoproliferative disorders: a prospective randomized study evaluating the efficacy of granulocyte-macrophage colony stimulating factor as a vaccine adjuvant. Eur J Haematol 2007; 79:292-6.
307. Pullukcu H, Ertem E, Karaca Y, Yamazhan T, Sertoz RY, Altuglu I. Efficacy of accelerated hepatitis B vaccination program in patients being actively treated for hematologic malignancies. Int J Infect Dis 2008; 12:166-70.
308. Ljungman P, Nahi H, Linde A. Vaccination of patients with haemato-logical malignancies with one or two doses of influenza vaccine: a randomised study. Br J Haematol 2005; 130:96-8.
309. Takata T, Suzumiya J, Ishikawa T, Takamatsu Y, Ikematsu H, Tamura K. Attenuated antibody reaction for the primary antigen but not for the recall antigen of influenza vaccination in patients with non-Hodgkin B-cell lymphoma after the administration of rituximab-CHOP. J Clin Exp Hematop 2009; 49:9-13.
310. Horwitz SM, Negrin RS, Blume KG, et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 2004; 103:777-83.
311. Lum LG, Seigneuret MC, Storb R. The transfer of antigen-specific humoral immunity from marrow donors to marrow recipients. J Clin Immunol 1986; 6:389-96.
312. Lum LG, Munn NA, Schanfield MS, Storb R. The detection of specific antibody formation to recall antigens after human bone marrow transplantation. Blood 1986; 67:582-7.
313. Lum LG. The kinetics of immune reconstitution after human marrow transplantation. Blood 1987; 69:369-80.
314. Lum LG, Noges JE, Beatty P, et al. Transfer of specific immunity in marrow recipients given HLA-mismatched, T cell-depleted, or HLA-identical marrow grafts. Bone Marrow Transplant 1988; 3:399-406.
315. Saxon A, Mitsuyasu R, Stevens R, Champlin RE, Kimata H, Gale RP. Designed transfer of specific immune responses with bone marrow transplantation. J Clin Invest 1986; 78:959-67.
316. Wahren B, Gahrton G, Linde A, et al. Transfer and persistence of viral antibody-producing cells in bone marrow transplantation. J Infect Dis 1984; 150:358-65.
317. Witherspoon RP, Storb R, Ochs HD, et al. Recovery of antibody production in human allogeneic marrow graft recipients: influence of time posttransplantation, the presence or absence of chronic graft-versus-host disease, and antithymocyte globulin treatment. Blood 1981; 58:360-8.
318. Witherspoon RP, Matthews D, Storb R, et al. Recovery of in vivo cellular immunity after human marrow grafting. Influence of time post-grafting and acute graft-versus-host disease. Transplantation 1984; 37:145-50.
319. Wimperis JZ, Brenner MK, Prentice HG, et al. Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-de-pleted bone marrow. Lancet 1986; 1:339-43.
320. Molrine DC, Hibberd PL. Vaccines for transplant recipients. Infect Dis Clin North Am 2001; 15:273-305, xii.
321. Molrine DC, Guinan EC, Antin JH, et al. Donor immunization with Haemophilus influenzae type b (HIB)-conjugate vaccine in allogeneic bone marrow transplantation. Blood 1996; 87:3012-8.
322. Ljungman P, Wiklund-Hammarsten M, Duraj V, et al. Response to tetanus toxoid immunization after allogeneic bone marrow transplantation. J Infect Dis 1990; 162:496-500.
323. Ljungman P, Duraj V, Magnius L. Response to immunization against polio after allogeneic marrow transplantation. Bone Marrow Transplant 1991; 7:89-93.
324. Engelhard D, Handsher R, Naparstek E, et al. Immune response to polio vaccination in bone marrow transplant recipients. Bone Marrow Transplant 1991; 8:295-300.
325. Parkkali T, Stenvik M, Ruutu T, Hovi T, Volin L, Ruutu P. Randomized comparison of early and late vaccination with inactivated poliovirus vaccine after allogeneic BMT. Bone Marrow Transplant 1997; 20:663-8.
326. Ljungman P, Lewensohn-Fuchs I, Hammarstrom V, et al. Long-term immunity to measles, mumps, and rubella after allogeneic bone marrow transplantation. Blood 1994; 84:657-63.
327. Machado CM, Goncalves FB, Pannuti CS, Dulley FL, de Souza VA. Measles in bone marrow transplant recipients during an outbreak in Sao Paulo, Brazil. Blood 2002; 99:83-7.
328. Parkman R, Weinberg KI. Immunological reconstitution following bone marrow transplantation. Immunol Rev 1997; 157:73-8.
329. Cristofani LM, Weinberg A, Peixoto V, et al. Administration of live attenuated varicella vaccine to children with cancer before starting chemotherapy. Vaccine 1991; 9:873-6.
330. Tsolia M, Gershon AA, Steinberg SP, Gelb L. Live attenuated varicella vaccine: evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group. J Pediatr 1990; 116:184-9.
331. Hardy I, Gershon AA, Steinberg SP, LaRussa P. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group. N Engl J Med 1991;325:1545-50.
332. Ljungman P, Ward KN, Crooks BN, et al. Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone
333. Ljungman P, de la Camara R, Perez-Bercoff L, et al. Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients. Haematologica 2011; 96:1231-5.
334. Choi SM, Boudreault AA, Xie H, Englund JA, Corey L, Boeckh M. Differences in clinical outcomes after 2009 influenza A/H1N1 and seasonal influenza among hematopoietic cell transplant recipients. Blood 2011; 117:5050-6.
335. Engelhard D, Zakay-Rones Z, Shapira MY, et al. The humoral immune response of hematopoietic stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1)v-like virus vaccine during the 2009 pandemic. Vaccine 2011; 29:1777-82.
336. Pauksen K, Linde A, Hammarstrom V, et al. Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients. Clin Infect Dis 2000; 30:342-8.
337. de Lavallade H, Garland P, Sekine T, et al. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocom-promised host. Haematologica 2011; 96:307-14.
338. Avetisyan G, Aschan J, Hassan M, Ljungman P. Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers and in patients after stem cell transplantation. Transplantation 2008; 86:257-63.
339. Haining WN, Evans JW, Seth NP, et al. Measuring T cell immunity to influenza vaccination in children after haemopoietic stem cell transplantation. Br J Haematol 2004; 127:322-5.
340. Gueller S, Allwinn R, Mousset S, et al. Enhanced immune response after a second dose of an AS03-adjuvanted H1N1 influenza A vaccine in patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011; 17:1546-50.
341. Engelhard D, Cordonnier C, Shaw PJ, et al. Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey. Br J Haematol 2002; 117:444-50.
342. Winston DJ, Schiffman G, Wang DC, et al. Pneumococcal infections after human bone-marrow transplantation. Ann Intern Med 1979; 91:835-41.
343. Kulkarni S, Powles R, Treleaven J, et al. Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. Blood 2000; 95:3683-6.
344. Youssef S, Rodriguez G, Rolston KV, Champlin RE, Raad II, Safdar A. Streptococcus pneumoniae infections in 47 hematopoietic stem cell transplantation recipients: clinical characteristics of infections and vaccine-breakthrough infections, 1989-2005. Medicine (Baltimore) 2007; 86:69-77.
345. Giebink GS, Warkentin PI, Ramsay NK, Kersey JH. Titers of antibody to pneumococci in allogeneic bone marrow transplant recipients before and after vaccination with pneumococcal vaccine. J Infect Dis 1986; 154:590-6.
346. Avanzini MA, Carra AM, Maccario R, et al. Antibody response to pneumococcal vaccine in children receiving bone marrow transplantation. J Clin Immunol 1995; 15:137-44.
347. Guinan EC, Molrine DC, Antin JH, et al. Polysaccharide conjugate vaccine responses in bone marrow transplant patients. Transplantation 1994; 57:677-84.
348. Parkkali T, Kayhty H, Ruutu T, Volin L, Eskola J, Ruutu P. A comparison of early and late vaccination with Haemophilus influenzae type b conjugate and pneumococcal polysaccharide vaccines after allogeneic BMT. Bone Marrow Transplant 1996; 18:961-7.
349. Winston DJ, Ho WG, Schiffman G, Champlin RE, Feig SA, Gale RP. Pneumococcal vaccination of recipients of bone marrow transplants. Arch Intern Med 1983; 143:1735-7.
350. Cordonnier C, Labopin M, Chesnel V, et al. Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation. Clin Infect Dis 2009; 48:1392-401.
351. Molrine DC, Antin JH, Guinan EC, et al. Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation. Blood 2003; 101:831-6.
352. Meisel R, Kuypers L, Dirksen U, et al. Pneumococcal conjugate vaccine provides early protective antibody responses in children after related and unrelated allogeneic hematopoietic stem cell transplantation. Blood 2007; 109:2322-6.
353. Kumar D, Chen MH, Welsh B, et al. A randomized, double-blind trial of pneumococcal vaccination in adult allogeneic stem cell transplant donors and recipients. Clin Infect Dis 2007; 45:1576-82.
354. Cordonnier C, Labopin M, Chesnel V, et al. Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: results from the EBMT IDWP01 trial. Vaccine 2010; 28:2730-4.
355. Hammarstrom V, Pauksen K, Azinge J, Oberg G, Ljungman P. Pneumococcal immunity and response to immunization with pneumococcal vaccine in bone marrow transplant patients: the influence of graft versus host reaction. Support Care Cancer 1993; 1:195-9.
356. Barra A, Cordonnier C, Preziosi MP, et al. Immunogenicity of Haemo-philus influenzae type b conjugate vaccine in allogeneic bone marrow recipients. J Infect Dis 1992; 166:1021-8.
357. Avanzini MA, Carra AM, Maccario R, et al. Immunization with Hae-mophilus influenzae type b conjugate vaccine in children given bone marrow transplantation: comparison with healthy age-matched controls. J Clin Immunol 1998; 18:193-201.
358. Parkkali T, Olander RM, Ruutu T, et al. A randomized comparison between early and late vaccination with tetanus toxoid vaccine after al-logeneic BMT. Bone Marrow Transplant 1997; 19:933-8.
359. Kochethu G, Clark FJ, Craddock CF. Pertussis: should we vaccinate post transplant? Bone Marrow Transplant 2006; 37:793-4.
360. Florax A, Ehlert K, Becker K, Vormoor J, Groll AH. Bordetella pertussis respiratory infection following hematopoietic stem cell transplantation: time for universal vaccination? Bone Marrow Transplant 2006; 38:639-40.
361. Small TN, Zelenetz AD, Noy A, et al. Pertussis immunity and response to tetanus-reduced diphtheria-reduced pertussis vaccine (Tdap) after autologous peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2009; 15:1538-42.
362. Papadopoulos E, Young J, Kernan NA, Boulad F, Castro-Malaspina H, O'Reilly RJ. Use of the tetanus toxoid, reduced dose diphtheria and pertussis vaccine (Tdap) in allogeneic transplant (alloHCT) recipients. Blood 2008; 112:2214.
363. Nagler A, Ilan Y, Adler R, et al. Successful immunization of autolo-gous bone marrow transplantation recipients against hepatitis B virus by active vaccination. Bone Marrow Transplant 1995; 15:475-8.
364. Jaffe D, Papadopoulos EB, Young JW, et al. Immunogenicity of recombi-nant hepatitis B vaccine (rHBV) in recipients of unrelated or related allo-geneic hematopoietic cell (HC) transplants. Blood 2006; 108:2470-5.
365. Nakano T, Shimono Y, Sugiyama K, et al. Clinical features of measles in immunocompromised children. Acta Paediatr Jpn 1996; 38:212-7.
366. Kaplan LJ, Daum RS, Smaron M, McCarthy CA. Severe measles in im-munocompromised patients. JAMA 1992; 267:1237-41.
367. Machado CM, de Souza VA, Sumita LM, da Rocha IF, Dulley FL, Pannuti CS. Early measles vaccination in bone marrow transplant recipients. Bone Marrow Transplant 2005; 35:787-91.
368. Spoulou V, Giannaki M, Vounatsou M, Bakoula C, Grafakos S. Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants. Bone Marrow Transplant 2004; 33:1187-90.
369. King SM, Saunders EF, Petric M, Gold R. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients. Bone Marrow Transplant 1996; 17:633-6.
370. Ljungman P, Fridell E, Lonnqvist B, et al. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. J Infect Dis 1989; 159:610-5.
371. Kussmaul SC, Horn BN, Dvorak CC, Abramovitz L, Cowan MJ, Wein-trub PS. Safety of the live, attenuated varicella vaccine in pediatric recipients of hematopoietic SCTs. Bone Marrow Transplant 2010; 45:1602-6.
372. Van Thiel DH, Gavaler JS. Response to HBV vaccination in patients with severe liver disease. Absence of an HLA effect. Dig Dis Sci 1992; 37:1447-51.
373. Danzinger-Isakov L, Kumar D. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 2009; 9 (Suppl 4):S258-62.
374. No authors listed. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 (Suppl 3):S1-155.
375. Kotton CN, Hibberd PL. Travel medicine and the solid organ transplant recipient. Am J Transplant 2009; 9 (Suppl 4):S273-81.
376. Kumar D, Blumberg EA, Danziger-Isakov L, et al. Influenza vaccination in the organ transplant recipient: review and summary recommendations. Am J Transplant 2011; 11:2020-30.
377. Campbell AL, Herold BC. Immunization of pediatric solid-organ transplantation candidates: immunizations in transplant candidates. Pediatr Transplant 2005; 9:652-61.
378. Laube GF, Berger C, Goetschel P, Leumann E, Neuhaus TJ. Immunization in children with chronic renal failure. Pediatr Nephrol 2002; 17:638-42.
379. Flynn JT, Frisch K, Kershaw DB, Sedman AB, Bunchman TE. Response to early measles-mumps-rubella vaccination in infants with chronic renal failure and/or receiving peritoneal dialysis. Adv Perit Dial 1999; 15:269-72.
380. Benden C, Danziger-Isakov LA, Astor T, et al. Variability in immunization guidelines in children before and after lung transplantation. Pediatr Transplant 2007; 11:882-7.
381. Wu JF, Ni YH, Chen HL, Hsu HY, Lai HS, Chang MH. Humoral im-munogenicity to measles, rubella, and varicella-zoster vaccines in biliary atresia children. Vaccine 2009; 27:2812-5.
382. Prelog M, Pohl M, Ermisch B, et al. Demand for evaluation of vaccination antibody titers in children considered for renal transplantation. Pediatr Transplant 2007; 11:73-6.
383. Duchini A, Hendry RM, Redfield DC, Pockros PJ. Influenza infection in patients before and after liver transplantation. Liver Transpl 2000; 6:531-42.
384. Furth SL, Neu AM, Case B, Lederman HM, Steinhoff M, Fivush B. Pneumococcal polysaccharide vaccine in children with chronic renal disease: a prospective study of antibody response and duration. J Pediatr 1996; 128:99-101.
385. Linnemann CC Jr., First MR, Schiffman G. Response to pneumococcal vaccine in renal transplant and hemodialysis patients. Arch Intern Med 1981; 141:1637-40.
386. Linnemann CC Jr., First MR, Schiffman G. Revaccination of renal transplant and hemodialysis recipients with pneumococcal vaccine. Arch Intern Med 1986; 146:1554-6.
387. Kruger S, Seyfarth M, Sack K, Kreft B. Defective immune response to tetanus toxoid in hemodialysis patients and its association with diphtheria vaccination. Vaccine 1999; 17:1145-50.
388. Lin CC, Chen CL, Concejero A, et al. Active immunization to prevent de novo hepatitis B virus infection in pediatric live donor liver recipients. Am J Transplant 2007; 7:195-200.
389. Wachs ME, Amend WJ, Ascher NL, et al. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation 1995; 59:230-4.
390. Crosnier J, Jungers P, Courouce AM, et al. Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemo-dialysis units: II, haemodialysis patients. Lancet 1981; 1:797-800.
391. Stevens CE, Alter HJ, Taylor PE, Zang EA, Harley EJ, Szmuness W. Hepatitis B vaccine in patients receiving hemodialysis. Immunogenici-ty and efficacy. N Engl J Med 1984; 311:496-501.
392. Villeneuve E, Vincelette J, Villeneuve JP. Ineffectiveness of hepatitis B vaccination in cirrhotic patients waiting for liver transplantation. Can J Gastroenterol 2000; 14 (Suppl B):59B-62B.
393. Carey W, Pimentel R, Westveer MK, Vogt D, Broughan T. Failure of hepatitis B immunization in liver transplant recipients: results of a prospective trial. Am J Gastroenterol 1990; 85:1590-2.
394. Arslan M, Wiesner RH, Sievers C, Egan K, Zein NN. Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease. Liver Transpl 2001; 7:314-20.
395. Engler SH, Sauer PW, Golling M, et al. Immunogenicity of two accelerated hepatitis B vaccination protocols in liver transplant candidates. Eur J Gastroenterol Hepatol 2001; 13:363-7.
396. Aziz A, Aziz S, Li DS, et al. Efficacy of repeated high-dose hepatitis B vaccine (80 microg) in patients with chronic liver disease. J Viral Hepat 2006; 13:217-21.
397. Schumann A, Lindemann M, Valentin-Gamazo C, et al. Adoptive immune transfer of hepatitis B virus specific immunity from immunized living liver donors to liver recipients. Transplantation 2009; 87:103-11.
398. Keeffe EB, Iwarson S, McMahon BJ, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatol-ogy 1998; 27:881-6.
399. Arslan M, Wiesner RH, Poterucha JJ, Zein NN. Safety and efficacy of hepatitis A vaccination in liver transplantation recipients. Transplantation 2001; 72:272-6.
400. Dumot JA, Barnes DS, Younossi Z, et al. Immunogenicity of hepatitis A vaccine in decompensated liver disease. Am J Gastroenterol 1999; 94:1601-4.
401. Geel AL, Landman TS, Kal JA, van Doomum GJ, Weimar W. Varicella zoster virus serostatus before and after kidney transplantation, and vaccination of adult kidney transplant candidates. Transplant Proc 2006; 38:3418-9.
402. Broyer M, Tete MJ, Guest G, Gagnadoux MF, Rouzioux C. Varicella and zoster in children after kidney transplantation: long-term results of vaccination. Pediatrics 1997; 99:35-9.
403. Furth SL, Hogg RJ, Tarver J, Moulton LH, Chan C, Fivush BA. Varicella vaccination in children with chronic renal failure. A report of the Southwest Pediatric Nephrology Study Group. Pediatr Nephrol 2003; 18:33-8.
404. Webb NJ, Fitzpatrick MM, Hughes DA, et al. Immunisation against varicella in end stage and pre-end stage renal failure. Trans-Pennine Paediatric Nephrology Study Group. Arch Dis Child 2000; 82:141-3.
405. Donati M, Zuckerman M, Dhawan A, et al. Response to varicella immunization in pediatric liver transplant recipients. Transplantation 2000; 70:1401-4.
406. Nithichaiyo C, Chongsrisawat V, Hutagalung Y, Bock HL, Poovorawa Y. Immunogenicity and adverse effects of live attenuated varicella vaccine (Oka-strain) in children with chronic liver disease. Asian Pac J Allergy Immunol 2001; 19:101-5.
407. Furth SL, Fivush BA. Varicella vaccination in pediatric kidney transplant candidates. Pediatr Transplant 2002; 6:97-100.
408. Sanchez-Fructuoso AI, Prats D, Naranjo P, et al. Influenza virus immunization effectivity in kidney transplant patients subjected to two different triple-drug therapy immunosuppression protocols: myco-phenolate versus azathioprine. Transplantation 2000; 69:436-9.
409. Versluis DJ, Beyer WE, Masurel N, Wenting GJ, Weimar W. Impairment of the immune response to influenza vaccination in renal transplant recipients by cyclosporine, but not azathioprine. Transplantation 1986; 42:376-9.
410. Soesman NM, Rimmelzwaan GF, Nieuwkoop NJ, et al. Efficacy of influenza vaccination in adult liver transplant recipients. J Med Virol 2000; 61:85-93.
411. Dengler TJ, Strnad N, Buhring I, et al. Differential immune response to influenza and pneumococcal vaccination in immunosuppressed patients after heart transplantation. Transplantation 1998; 66:1340-7.
412. Fraund S, Wagner D, Pethig K, Drescher J, Girgsdies OE, Haverich A. Influenza vaccination in heart transplant recipients. J Heart Lung Transplant 1999; 18:220-5.
413. Magnani G, Falchetti E, Pollini G, et al. Safety and efficacy of two types of influenza vaccination in heart transplant recipients: a prospective randomised controlled study. J Heart Lung Transplant 2005; 24:588-92.
414. Furth SL, Neu AM, McColley SA, Case B, Steinhoff M, Fivush B. Immune response to influenza vaccination in children with renal disease. Pediatr Nephrol 1995; 9:566-8.
415. Madan RP, Tan M, Fernandez-Sesma A, et al. A prospective, comparative study of the immune response to inactivated influenza vaccine in pediatric liver transplant recipients and their healthy siblings. Clin Infect Dis 2008; 46:712-8.
416. Hayney MS, Welter DL, Francois M, Reynolds AM, Love RB. Influenza vaccine antibody responses in lung transplant recipients. Prog Transplant 2004; 14:346-51.
417. Blumberg EA, Fitzpatrick J, Stutman PC, Hayden FG, Brozena SC. Safety of influenza vaccine in heart transplant recipients. J Heart Lung Transplant 1998; 17:1075-80.
418. Burbach G, Bienzle U, Stark K, et al. Influenza vaccination in liver transplant recipients. Transplantation 1999; 67:753-5.
419. Mazzone PJ, Mossad SB, Mawhorter SD, Mehta AC, Schilz RJ, Maurer JR. The humoral immune response to influenza vaccination in lung transplant patients. Eur Respir J 2001; 18:971-6.
420. Salles MJ, Sens YA, Boas LS, Machado CM. Influenza virus vaccination in kidney transplant recipients: serum antibody response to different immunosuppressive drugs. Clin Transplant 2010; 24:E17-23.
421. Mazzone PJ, Mossad SB, Mawhorter SD, Mehta AC, Mauer JR. Cell-mediated immune response to influenza vaccination in lung transplant recipients. J Heart Lung Transplant 2004; 23:1175-81.
422. Hurst FP, Lee JJ, Jindal RM, Agodoa LY, Abbott KC. Outcomes associated with influenza vaccination in the first year after kidney transplantation. Clin J Am Soc Nephrol 2011; 6:1192-7.
423. Baluch A, Humar A, Eurich D, et al. Randomized controlled trial of high-dose intradermal versus standard-dose intramuscular influenza vaccine in organ transplant recipients. Am J Transplant 2013; 13:1026-33.
424. Kazancioglu R, Sever MS, Yuksel-Onel D, et al. Immunization of renal transplant recipients with pneumococcal polysaccharide vaccine. Clin Transplant 2000; 14:61-5.
425. Blumberg EA, Brozena SC, Stutman P, Wood D, Phan HM, Musher DM. Immunogenicity of pneumococcal vaccine in heart transplant recipients. Clin Infect Dis 2001; 32:307-10.
426. McCashland TM, Preheim LC, Gentry MJ. Pneumococcal vaccine response in cirrhosis and liver transplantation. J Infect Dis 2000; 181:757-60.
427. Kumar D, Rotstein C, Miyata G, Arlen D, Humar A. Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients. J Infect Dis 2003; 187:1639-45.
428. Kumar D, Welsh B, Siegal D, Chen MH, Humar A. Immunogenicity of pneumococcal vaccine in renal transplant recipients-three year follow-up of a randomized trial. Am J Transplant 2007; 7:633-8.
429. Kumar D, Chen MH, Wong G, et al. A randomized, double-blind, placebo-controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in adult liver transplant recipients. Clin Infect Dis 2008; 47:885-92.
430. Lin PL, Michaels MG, Green M, et al. Safety and immunogenicity of the American Academy of Pediatrics-recommended sequential pneumococcal conjugate and polysaccharide vaccine schedule in pediatric solid organ transplant recipients. Pediatrics 2005; 116:160-7.
431. Barton M, Wasfy S, Dipchand AI, et al. Seven-valent pneumococcal conjugate vaccine in pediatric solid organ transplant recipients: a prospective study of safety and immunogenicity. Pediatr Infect Dis J 2009; 28:688-92.
432. Enke BU, Bokenkamp A, Offner G, Bartmann P, Brodehl J. Response to diphtheria and tetanus booster vaccination in pediatric renal transplant recipients. Transplantation 1997; 64:237-41.
433. Duca P, Del Pont JM, D'Agostino D. Successful immune response to a recombinant hepatitis B vaccine in children after liver transplantation. J Pediatr Gastroenterol Nutr 2001; 32:168-70.
434. Sanchez-Fueyo A, Rimola A, Grande L, et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 2000; 31:496-501.
435. Di Paolo D, Lenci I, Trinito MO, Tisone G, Angelico M. Extended HBV vaccination in liver transplant recipients for HBV-related cirrhosis: report of two successful cases. Dig Liver Dis 2005; 37:793-8.
436. Arslan M, Wiesner RH, Poterucha JJ, Gross JB Jr., Zein NN. Hepatitis A antibodies in liver transplant recipients: evidence for loss of immunity posttransplantation. Liver Transpl 2000; 6:191-5.
437. Gunther M, Stark K, Neuhaus R, Reinke P, Schroder K, Bienzle U. Rapid decline of antibodies after hepatitis A immunization in liver and renal transplant recipients. Transplantation 2001; 71:477-9.
438. Kwak EJ, Julian K. Human papillomavirus infection in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl 4):S151-60.
439. Khan S, Erlichman J, Rand EB. Live virus immunization after ortho-topic liver transplantation. Pediatr Transplant 2006; 10:78-82.
440. Levitsky J, Te HS, Faust TW, Cohen SM. Varicella infection following varicella vaccination in a liver transplant recipient. Am J Transplant 2002; 2:880-2.
441. Posfay-Barbe KM, Pittet LF, Sottas C, et al. Varicella-zoster immunization in pediatric liver transplant recipients: safe and immunogenic. Am J Transplant 2012; 12:2974-85.
442. Lawal A, Basler C, Branch A, Gutierrez J, Schwartz M, Schiano TD. Influenza vaccination in orthotopic liver transplant recipients: absence of post administration ALT elevation. Am J Transplant 2004; 4:1805-9.
443. Kimball P, Verbeke S, Flattery M, Rhodes C, Tolman D. Influenza vaccination does not promote cellular or humoral activation among heart transplant recipients. Transplantation 2000; 69:2449-51.
444. White-Williams C, Brown R, Kirklin J, et al. Improving clinical practice: should we give influenza vaccinations to heart transplant patients? J Heart Lung Transplant 2006; 25:320-3.
445. Danziger-Isakov L, Cherkassky L, Siegel H, et al. Effects of influenza immunization on humoral and cellular alloreactivity in humans. Transplantation 2010; 89:838-44.
446. Lu Y, Jacobson DL, Ashworth LA, et al. Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroen-terol 2009; 104:444-53.
447. Mamula P, Markowitz JE, Piccoli DA, Klimov A, Cohen L, Baldassano RN. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5:851-6.
448. Kanakoudi-Tsakalidou F, Trachana M, Pratsidou-Gertsi P, Tsitsami E, Kyriazopoulou-Dalaina V. Influenza vaccination in children with chronic rheumatic diseases and long-term immunosuppressive therapy. Clin Exp Rheumatol 2001; 19:589-94.
449. Elkayam O, Bashkin A, Mandelboim M, et al. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondyli-tis. Semin Arthritis Rheum 2009; 63:1062-7.
450. Abu-Shakra M, Press J, Varsano N, et al. Specific antibody response after influenza immunization in systemic lupus erythematosus. J Rheumatol 2002; 29:2555-7.
451. Holvast A, Huckriede A, Wilschut J, et al. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis 2006; 65:913-8.
452. Fomin I, Caspi D, Levy V, et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis 2006; 65:191-4.
453. van Assen S, Holvast A, Benne CA, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010; 62:75-81.
454. Mori S, Ueki Y, Hirakata N, Oribe M, Hidaka T, Oishi K. Impact of to-cilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis. Ann Rheum Dis 2012; 71:2006-10.
455. Shinoki T, Hara R, Kaneko U, et al. Safety and response to influenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving tocilizumab. Mod Rheumatol 2012; 22:871-6.
456. Saad CG, Borba EF, Aikawa NE, et al. Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases. Ann Rheum Dis 2011; 70:1068-73.
457. Elkayam O, Amir S, Mendelson E, et al. Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases. Arthritis Care Res (Hoboken) 2011; 63:1062-7.
458. Gabay C, Bel M, Combescure C, et al. Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum 2011; 63:1486-96.
459. Kapetanovic MC, Saxne T, Sjoholm A, Truedsson L, Jonsson G, Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006; 45:106-11.
460. Visvanathan S, Keenan GF, Baker DG, Levinson AI, Wagner CL. Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone. J Rheumatol 2007; 34:952-7.
461. Mease PJ, Ritchlin CT, Martin RW, et al. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol 2004; 31:1356-61.
462. Bingham CO 3rd, Looney RJ, Deodhar A, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 2010; 62:64-74.
463. Mori S, Ueki Y, Akeda Y, et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. Ann Rheum Dis 2013.
464. Farmaki E, Kanakoudi-Tsakalidou F, Spoulou V, et al. The effect of anti-TNF treatment on the immunogenicity and safety of the 7-valent conjugate pneumococcal vaccine in children with juvenile idiopathic arthritis. Vaccine 2010; 28:5109-13.
465. Zonneveld-Huijssoon E, Ronaghy A, Van Rossum MA, et al. Safety and efficacy of meningococcal c vaccination in juvenile idiopathic arthritis. Arthritis Rheum 2007; 56:639-46.
466. Elkayam O, Yaron M, Caspi D. Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. Ann Rheum Dis 2002; 61:623-5.
467. Cush J. Herpes Zoster (Shingles) Vaccine Guidelines for Immunosup-pressed Patients. American College of Rheumatology Hotline 2008 Available at: http://www.rheumatology.org/publications/hotline/2008- 08-01-shingles.asp.
468. Borte S, Liebert UG, Borte M, Sack U. Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. Rheumatology (Oxford) 2009; 48:144-8.
469. Heijstek MW, Kamphuis S, Armbrust W, et al. Effects of the live attenuated measles-mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis: a randomized trial. JAMA 2013; 309:2449-56.
470. Chalmers A, Scheifele D, Patterson C, et al. Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity. J Rheumatol 1994; 21:1203-6.
471. Holvast A, van Assen S, de Haan A, et al. Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: an open, prospective, controlled study. Rheumatology (Oxford) 2009; 48:1294-9.
472. Wallin L, Quintilio W, Locatelli F, Cassel A, Silva MB, Skare TL. Safety and efficiency of influenza vaccination in systemic lupus erythemato-sus patients. Acta Reumatol Port 2009; 34:498-502.
473. Kuruma KA, Borba EF, Lopes MH, de Carvalho JF, Bonfa E. Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus. Lupus 2007; 16:350-4.
474. Elkayam O, Paran D, Caspi D, et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis 2002; 34:147-53.
475. Vernacchio L, Neufeld EJ, MacDonald K, et al. Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneu-mococcal vaccine in children and young adults with sickle cell disease. J Pediatr 1998; 133:275-8.
476. Shatz DV, Schinsky MF, Pais LB, Romero-Steiner S, Kirton OC, Carlone GM. Immune responses of splenectomized trauma patients to the 23-valent pneumococcal polysaccharide vaccine at 1 versus 7 versus 14 days after splenectomy. J Trauma 1998; 44:760-5; discussion 65-6.
477. Shatz DV, Romero-Steiner S, Elie CM, Holder PF, Carlone GM. Antibody responses in postsplenectomy trauma patients receiving the 23-valent pneumococcal polysaccharide vaccine at 14 versus 28 days post-operatively. J Trauma 2002; 53:1037-42.
478. Konradsen HB, Rasmussen C, Ejstrud P, Hansen JB. Antibody levels against Streptococcus pneumoniae and Haemophilus influenzae type b in a population of splenectomized individuals with varying vaccination status. Epidemiol Infect 1997; 119:167-74.
479. Newcomer W, Santosham M, Bengston S, Panny S, Dover G. Immu-nogenicity of Haemophilus influenzae type b polysaccharide and Neis-seria meningitidis outer membrane protein complex conjugate vaccine in infants and children with sickle cell disease. Pediatr Infect Dis J 1993; 12:1026-7.
480. Jakacki R, Luery N, McVerry P, Lange B. Haemophilus influenzae diphtheria protein conjugate immunization after therapy in splenectomized patients with Hodgkin disease. Ann Intern Med 1990; 112:143-4.
481. No authors listed. Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococ-cal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease. MMWR Morb Mortal Wkly Rep 2011; 60:1391-2.
482. Administration FaD. Product approval information: package insert. Menactra (meningococcal (groups A, C, Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine), 2011. Available at: http://www. fda.gov/downloads/ biologicsbloodvaccines/vaccines/approvedproducts/ucm131170.pdf. Accessed 12 April 2011.
483. Rubin LG, Papsin B. Cochlear implants in children: surgical site infections and prevention and treatment of acute otitis media and meningitis. Pediatrics 2010; 126:381-91.
484. Rose M, Hey C, Kujumdshiev S, Gall V, Schubert R, Zielen S. Immu-nogenicity of pneumococcal vaccination of patients with cochlear implants. J Infect Dis 2004; 190:551-7.